☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Yearly Bisphosphonate!

An interim analysis of the HORIZON study was presented at the annual meeting of the American Society of Bone and Mineral Research.

The Health Outcomes and Reduced Incidence with Zoledronic acid Once yearly (Horizon) study aimed to assess the impact of an annual dose of zoledronic acid on the rate of fractures in postmenopausal women.

The complete data are not yet available however a press release claims that the early analysis shows that results appear promising for the drug.

The obvious major drawback is that the drug is formulated as an intravenous infusion and delivering it in primary care raises challenges.

Action: The investigated indication is currently unlicensed. If a licence extension is granted the challenges presented by intravenous administration are likely to significantly limit use.

Share 'Yearly Bisphosphonate!' by emailShare 'Yearly Bisphosphonate!' on FacebookShare 'Yearly Bisphosphonate!' on TwitterShare 'Yearly Bisphosphonate!' on LinkedInShare 'Yearly Bisphosphonate!' on reddit


No Comments to “Yearly Bisphosphonate!”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.